PDF(Pubmed)
Abstract：
UNASSIGNED: Colorectal cancer (CRC) ranks third in highest incidence among human cancers. With the continuous development of anti-cancer drugs, CRC patients are treated more and more effectively. However, the treatment of patients with unresectable metastatic CRC (mCRC) remains a core point for surgeons worldwide, especially for those with microsatellite stability (MSS) and BRAF V600E mutation, who have been reported to have the worst prognosis.
UNASSIGNED: We report a case of pathological complete remission in a patient with unresectable MSS, BRAF V600E-mutated metastatic rectal cancer after using Vemurafenib and Cetuximab in combination with Camrelizumab.
UNASSIGNED: This case suggested that Vemurafenib and Cetuximab combined with Camrelizumab is effective in the treatment of MSS, BRAF V600E-mutated mCRC. To benefit more patients, further studies need to be completed.
UNASSIGNED: We report a case of pathological complete remission in a patient with unresectable MSS, BRAF V600E-mutated metastatic rectal cancer after using Vemurafenib and Cetuximab in combination with Camrelizumab.
UNASSIGNED: This case suggested that Vemurafenib and Cetuximab combined with Camrelizumab is effective in the treatment of MSS, BRAF V600E-mutated mCRC. To benefit more patients, further studies need to be completed.
摘要：
未经证实：结直肠癌（CRC）在人类癌症中发病率最高的排名第三。随着抗癌药物的不断发展,CRC患者的治疗越来越有效。然而,不可切除的转移性CRC(mCRC)患者的治疗仍然是全世界外科医生的核心要点,特别是对于那些具有微卫星稳定性（MSS）和BRAFV600E突变，据报道预后最差的人。
未经证实：我们报告一例病理性完全缓解的患者，患有不可切除的MSS，使用Vemurafenib和西妥昔单抗联合Camrelizumab后，BRAFV600E突变的转移性直肠癌。
UNASSIGNED：该病例提示维罗非尼和西妥昔单抗联合卡姆瑞珠单抗治疗MSS有效，BRAFV600E突变的mCRC。让更多患者受益，需要进一步的研究。
未经证实：我们报告一例病理性完全缓解的患者，患有不可切除的MSS，使用Vemurafenib和西妥昔单抗联合Camrelizumab后，BRAFV600E突变的转移性直肠癌。
UNASSIGNED：该病例提示维罗非尼和西妥昔单抗联合卡姆瑞珠单抗治疗MSS有效，BRAFV600E突变的mCRC。让更多患者受益，需要进一步的研究。
